secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ovid Therapeutics Inc. (OVID)
CIK:        0001636651
Form:       8-K
Filed at:   2025-12-11T23:59:59+00:00
Accession:  0001636651-25-000017
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Ovid Therapeutics stockholders approve 3 proposals at special meeting including authorized share increase to 315M
--------------------------------------------------------------------------------

- Approved amendment to increase authorized common shares from 125M to 315M: 34.2M for, 1.5M against, 2.4M abstain.
- Approved issuance of shares upon conversion of Series B Preferred and exercise of Series A/B Warrants: 34.3M for, 1.3M against, 2.5M abstain.
- Approved issuance of securities to CEO Jeremy Levin under Oct 2, 2025 Securities Purchase Agreement: 34.3M for, 1.2M against, 2.5M abstain.
- Special meeting held Dec 11, 2025; quorum 38.0M of 71.2M outstanding shares (53.42%).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636651/000163665125000017/0001636651-25-000017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636651/000163665125000017/ovid-20251211.htm
  HTML page:      https://secwatch.observer/filing/0001636651-25-000017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer